Physician profile
Brian Nichols
NPI 1699727172
$873.66
in general payments reported to CMS, 2019-2025
15 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $96.10 · 2021: $13.87 · 2022: $131 · 2023: $315 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424 · Education: $14.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.56 |
| Education | $14.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $238.54 | 2019-2023 | Clareon |
| Glaukos Corporation | $132.04 | 2023 | |
| Rxsight INC | $86.99 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Abbvie INC. | $78.00 | 2023-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $69.60 | 2019 | |
| Travere Therapeutics, INC. | $46.51 | 2019-2023 | Cholbam |
| Heidelberg Engineering, INC. | $35.79 | 2022 | |
| Apellis Pharmaceuticals, INC. | $31.79 | 2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $28.63 | 2025 | Xdemvy |
| Allergan, INC. | $25.73 | 2019 | |
| Genentech USA, INC. | $23.56 | 2023 | Vabysmo |
| Thea Pharma INC. | $23.11 | 2022 | |
| Katena Products, INC. (Dba Corza Medical) | $19.76 | 2019 | |
| Ivantis, INC | $17.46 | 2020 | |
| Bausch & Lomb Americas INC. | $16.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.